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Abstract
Aim To investigate the cost-effectiveness of liraglutide as add-on to metformin vs. glimepiride or sitagliptin in patients with
Type 2 diabetes uncontrolled with ﬁrst-line metformin.
Methods Data were sourced from a clinical trial comparing liraglutide vs. glimepiride, both in combination with metformin,
and a clinical trial comparing liraglutide vs. sitagliptin, both as add-on to metformin. Only the subgroup of patients in whom
liraglutidewasaddedtometforminmonotherapywasincludedinthecost–utilityanalysis.TheCOREDiabetesModelwasused
to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients’ lifetimes.
Treatment effects were taken directly from the trials. Costs and outcomes were discounted at 3.5% per annum and costs were
accounted from a third-party payer (UK National Health System) perspective.
Results Treatmentwithliraglutide1.2and1.8 mgresulted,respectively,inmeanincreasesinquality-adjustedlifeexpectancy
of 0.32  0.15 and 0.28  0.14 quality-adjusted life years vs. glimepiride, and 0.19  0.15 and 0.31  0.15 quality-adjusted
life years vs. sitagliptin, and was associated with higher costs of £3003  £678 and £4688  £639 vs. glimepiride, and
£1842  £751 and £3224  £683 vs. sitagliptin, over a patient’s lifetime. Both liraglutide doses were cost-effective, with
incrementalcost-effectivenessratiosof£9449and£16 501perquality-adjustedlifeyeargainedvs.glimepiride,and£9851and
£10 465 per quality-adjusted life year gained vs. sitagliptin, respectively.
Conclusions Liraglutide,addedtometforminmonotherapy,isacost-effectiveoptionforthetreatmentofType 2diabetesina
UK setting.
Diabet. Med. 29, 313–320 (2012)
Keywords cost-effectiveness, liraglutide, Type 2 diabetes, UK
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Introduction
Diabetes is among the most common chronic illnesses
worldwide, with Type 2 diabetes mellitus accounting for
approximately 90% of all cases [1]. Type 2 diabetes is
progressive and is characterized by increased insulin resistance,
generally associated with obesity, and deteriorating b-cell
function, resulting in chronic hyperglycaemia. As the disease
progresses, so do the micro- and macrovascular complications
associatedwithit,whichhaveanegativeimpactonthequalityof
life of patients and pose a huge economic burden to the health
system[2,3].Forexample,in theUK,thecostofType 2 diabetes
accounts for 7–12% of the total National Health Service (NHS)
expenditure [4].
The risk of micro- and macrovascular complications is
strongly associated with hyperglycaemia, and each reduction of
11 mmol⁄mol (1%) in HbA1c signiﬁcantly reduces the risk of
developing these complications in patients with Type 2
diabetes [5]. In the UK, the National Institute for Health and
Clinical Excellence (NICE) recently issued recommendations
for the optimum management of Type 2 diabetes, taking into
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the available treatments (NICE, 2009) [6]. NICE recommends
lifestyle modiﬁcations and metformin as ﬁrst-line therapy, with
the subsequent stepwise additions of a sulphonylurea and
insulin. A thiazolidinedione or a dipeptidyl peptidase-4 (DPP-4)
inhibitor may be considered as second-line options in place of a
sulphonylurea if there is a signiﬁcant risk of hypoglycaemia,
or if a sulphonylurea is contraindicated or not tolerated.
Sitagliptin (a DPP-4 inhibitor) or a thiazolidinedione can be
considered as third-line therapy in place of insulin if insulin is
unacceptable. Exenatide may also be considered as a third-line
option in combination with metformin and a sulphonylurea in
patients with a BMI above 35 kg⁄m
2 and problems associated
with high weight, or BMI under 35 kg⁄m
2 if insulin is
unacceptable because of occupational implications, or if
weight loss would beneﬁt other co-morbidities [6]. The place
of liraglutide (Victoza
 ; Novo Nordisk A⁄S, Bagsvaerd,
Denmark) in therapy has also been evaluated recently by
NICE [7].
Recommendations advocate the use of liraglutide 1.2 mg
daily in triple therapy (with metformin and a sulphonylurea or
metformin and a thiazolidinedione) under the same conditions
described for exenatide, and in dual therapy (with metformin
or a sulphonylurea) if metformin or sulphonylureas and
thiazolidinediones or DPP-4 inhibitors cannot be tolerated or
are contraindicated [7]. The American Diabetes Association
and the European Association for the Study of Diabetes issued
similar recommendations in a consensus algorithm based on
effectiveness and safety data from clinical trials and on clinical
experience, taking into account beneﬁts, risks and costs of the
different available treatments [8]. In clinical trials, glucagon-
like peptide 1 (GLP-1) receptor agonists, such as liraglutide
and exenatide, have been shown to reduce HbA1c to at least
the same, and often to a greater, extent than traditional oral
hypoglycaemic agents and both Glucagon-like peptide (GLP-1)
receptor agonists and DPP-4 inhibitors such as Sitagliptin,
have the additional advantages of reducing the risk of
hypoglycaemia, as their insulinotropic effect is glucose-
dependent, and inducing weight loss (in the case of GLP-1
receptor agonists) or being weight-neutral (in the case of DPP-4
inhibitors) [9]. Additionally, GLP-1 receptor agonists have
been shown to have a positive effect on systolic blood pressure
[9]. Despite these advantages, sulphonylureas continue to be
the preferred second-line choice after metformin, with incretin-
based therapies only recommended as second- or third-line
therapies in special circumstances [6,8]. The fact that incretin-
based therapies are considered more expensive may contribute
to these therapies not being recommended more widely.
Liraglutide is a GLP-1 analogue approved in 2009 for use
in Europe, including the UK. Because of its recent approval,
studies evaluating the cost-effectiveness of liraglutide are
scarce. The aim of our study was to investigate the cost-
effectiveness of liraglutide as add-on to metformin compared
with glimepiride or sitagliptin in patients failing treatment
with ﬁrst-line metformin.
Patients and methods
Data sources
The cost–utility evaluation carried out in this study is based on
patients who participated in two studies performed as part of
the phase III clinical development programme for liraglutide: a
study comparing liraglutide vs. glimepiride (LEAD-2 study),
both in combination with metformin, and a study comparing
liraglutide vs. sitagliptin, both also in combination with
metformin [10,11]. In the LEAD-2 study, adults with Type 2
diabetes and HbA1c between 53 and 97 mmol⁄mol (7–11%)
(if previously treated with oral hypoglycaemic agent
monotherapy for at least 3 months) or HbA1c between 53
and 86 mmol⁄mol (7–10%) (if previously treated with oral
hypoglycaemic agent combination therapy for at least 3
months) were included. Additional inclusion criteria were age
between 18 and 80 years and BMI £ 40 kg⁄m
2. To facilitate
recruitment into the trial, previous treatment with other oral
anti-diabetes drugs, as monotherapy or in combination, was
allowed [10]. However, only the subgroup of patients in which
liraglutide or glimepiride was added to metformin mono-
therapy (approximately 30% of the total trial population) was
included in the cost–utility analysis presented here, as this was
considered to be more reﬂective of actual clinical practice. In
the liraglutide vs. sitagliptin study, adults with Type 2 diabetes,
previously treated with metformin monotherapy for at least
3 months and with HbA1c between 58 and 86 mmol⁄mol
(7.5–10.0%) were included. Additional inclusion criteria were
age between 18 and 80 years and BMI £ 45 kg⁄m
2 [11].
Demographic characteristics of the patients enrolled in these
studies have previously been described [10,11].
The CORE Diabetes Model
The cost–utility evaluation presented here was carried out using
theCOREDiabetesModel,detailsofwhichhavebeenpublished
previously by Palmer et al. [12]. The CORE diabetes model is a
validated [13] non-product-speciﬁc policy analysistoolbased on
a series of 15 sub-models that simulate major complications of
diabetes: cardiovascular disease, stroke, neuropathy, foot
ulcer⁄amputation, eye disease, nephropathy, hypoglycaemia,
lactic acidosis and non-speciﬁc mortality [12]. For each sub-
model, a combination of semi-Markov model structure and
Monte Carlo simulations were used. This structure allows
patients to develop multiple complications within each model
cycle and over the simulation period. The model projects
outcomes for populations, considering baseline cohort
characteristics, past history of complications, concomitant
medications, current and future diabetes management,
screening strategies and changes in physiological variables over
time. In this way, incidence of complications, life expectancy,
quality-adjusted life expectancy and total costs within
populations can be calculated. The results can be expressed in
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incremental cost-effectiveness ratios, i.e. the cost per QALY
gained. An incremental cost-effectiveness ratio threshold of
£20 000–30 000 per QALY gained is generally considered to
represent good value for money in the UK [14].
Simulation cohorts and treatments
A simulated cohort of patients was deﬁned (Table 1), with
baseline demographics and complications taken from the
respective clinical trial used in the analysis. Treatment effects
with liraglutide (1.2 and 1.8 mg) vs. glimepiride and liraglutide
(1.2 and 1.8 mg) vs. sitagliptin were taken directly from the
clinical trials (Table 2). Treatment duration was set to 5 years,
after which basal insulin therapy was started in an attempt to
replicate clinical practice. Simulations were run over patients’
lifetimes to capture all events and complications related to the
progression of Type 2 diabetes.
Costs and utilities
Costs were accounted from a third-party payer (National
Health Service) perspective. Where possible, unit costs for
complications were derived from UK-speciﬁc published
sources in patients with Type 2 diabetes and inﬂated to
2008 values, the latest available at the time of analysis, using
the composite National Health Service price inﬂation index
from the Personal Social Services Research Unit (PSSRU). A
summary of the costs of medicines and complications is given
in the Supporting Information (Table S1). The utilities used in
the base case presented here are summarized in the Supporting
Information (Table S2). The costs of medicines, self-monitored
blood glucose testing equipment and needles were taken from
the Monthly Index of Medical Specialities (MIMS) August
2009 [15]. Utilities and disutilities (i.e. measures of the impact
on quality of life) associated with complications of diabetes
were obtained from the literature and, where possible, taken
from populations with Type 2 diabetes. Discount rates of
3.5% per annum for both costs and clinical outcomes were
applied in the base case.
Sensitivity analyses
To assess the impact of varying the key assumptions and
outcomes used in the base-case analysis, several sensitivity
analyses were performed: treatment duration was set to 3 and
8 years; an alternative weight progression was used in which,
when treatment is switched, BMI reverts to baseline level and
then increases as predicted with insulin treatment; discount rates
were set to 0 and 6% for both costs and outcomes; and
hypoglycaemia disutility was removed and also set to 0.0052, as
usedinthetechnologyappraisalofinsulinglarginecarriedoutby
NICE[18].Additionalanalysestoinvestigatethecontributionof
individual clinical effects (weight, cholesterol and triglycerides,
systolic blood pressure and HbA1c) to quality-adjusted life
expectancy were also performed. The values used in the
sensitivity analyses were derived from expert consensus or were
previouslyusedby,orrecommendedby,NICEinitsGuidetothe
Methods of Technology Appraisal [16,17]. The results of these
analyses are presented as approximate relative impacts of the
base-case beneﬁt. It should be noted that these values represent
crude approximations (and therefore will not typically sum to
100%), as sensitivity analyses reﬂecting changes in multiple
clinicalvariableshaveacompleximpactonoutcomes(inrelation
to the base case).
Statistical methodology
A non-parametric bootstrapping approach was used for this
health economic analysis. Using second-order Monte Carlo
simulation, Type 2 diabetes progression was simulated in 1000
patientsthroughthemodel1000timestocalculatethemeanand
standard deviation of life expectancy, quality-adjusted life
expectancy, and costs [12]. The results from the bootstrapped
Table 1 Baselinepatientcharacteristicsintheliraglutidevs.glimepirideand
liraglutide vs. sitagliptin studies
Liraglutide
vs. glimepiride
(n = 263)*
Liraglutide
vs. sitagliptin
(n = 635)
Patient demographics
Age (years) 55.8 (9.0) 55.3 (9.2)
Diabetes duration
(years)
6 (5) 6 (5)
Proportion male (%) 54.2 52.9
Risk factors
HbA1c (mmol⁄mol) 67 (8.9) 68 (6.5)
(%) 8.3 (1.1) 8.4 (0.8)
Systolic blood pressure
(mmHg)
130.6 (14.0) 132.2 (14.5)
Body mass index
(kg⁄m
2)
31.0 (4.7) 32.8 (5.2)
Total cholesterol
(mmol⁄l)
4.88 (1.12) 4.09 (1.14)
HDL-C (mmol⁄l) 1.29 (0.33) 1.16 (0.31)
LDL-C (mmol⁄l) 3.11 (0.89) 2.65 (0.82)
Triglycerides (mmol⁄l) 2.19 (1.66) 2.38 (2.22)
Current smoker (%) 19.3* 19.3
Cigarettes ⁄day
 10 10
Alcohol consumption
(Oz⁄week)
55
Ethnic group (%)
Caucasian 88.5 90.0
Black 2.4 7.5
Hispanic 0 0
Native American 0 0.5
Asian⁄Paciﬁc Islander 9.1 0.2
*Subgroup of patients from LEAD-2 in which liraglutide or
glimepiride was added to metformin monotherapy.
Smoking status from Scottish Diabetes Survey 2007 [24];
cigarette and alcohol consumption are estimates.
The numbers in parentheses indicate standard deviation.
ª 2011 The Authors.
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curves.
Results
Base-case analyses
Liraglutide vs. glimepiride
Treatmentwithliraglutide 1.2and1.8 mgresulted,respectively,
in a mean increase in quality-adjusted life expectancy of 0.32 
0.15 QALYs and 0.28  0.14 QALYs, and was associated with
higher costs of £3003  £678 and £4688  £639 over a
patient’s lifetime, compared with glimepiride. The estimated
incremental cost-effectiveness ratios for liraglutide 1.2 and
1.8 mg vs. glimepiride were, respectively, £9449 and £16 501
per QALY gained (Table 3). At a willingness to pay of £20 000
perQALYgained,liraglutide1.2 mgisacost-effectivetreatment
optioninover88%ofcases,whereasliraglutide1.8 mgisacost-
effective treatment option in over 65% of cases. If the
willingness-to-pay threshold is increased to £30 000, the
probability that the treatment will be cost-effective increases to
over 93% for liraglutide 1.2 mg and 83% for liraglutide 1.8 mg
(Fig.1 ) .
Liraglutide vs. sitagliptin
Compared with sitagliptin, mean increases in quality-adjusted
life expectancy of 0.19  0.15 QALYs and 0.31  0.15
QALYs, and higher costs of £1842  £751 and £3224  £683
were associated with liraglutide 1.2 and 1.8 mg, respectively,
over a patient’s lifetime. The estimated incremental cost-
effectiveness ratios for liraglutide 1.2 and 1.8 mg vs. sitagliptin
were, respectively, £9851 and £10 465 per QALY gained
(Table 3). At a willingness to pay of £20 000, liraglutide
1.2 mg is a cost-effective treatment option in over 77% of
cases,whileliraglutide1.8 mgisacost-effectivetreatmentoption
in over 85% of cases. The probability that the treatment will be
cost-effective increases to 82% for liraglutide 1.2 mg and 92%
for liraglutide 1.8 mg when the willingness-to-pay threshold is
increased to £30 000.
Sensitivity analyses
Liraglutide vs. glimepiride and liraglutide vs. sitagliptin
Decreasing the discount rate resulted in a lower incremental
cost-effectiveness ratio with liraglutide 1.2 mg, while increasing
the discount rate increased the incremental cost-effectiveness
ratio.Reducingtreatmentdurationfrom5to3 yearsresultedina
lower incremental cost-effectiveness ratio for liraglutide 1.2 mg
(Table 4). In the shorter treatment duration simulation, the full
clinical beneﬁt of liraglutide was achieved, but the cost was
reduced as liraglutide pharmacy costs were only accounted for
3 years. Increasing treatment duration to 8 years resulted in a
higherincrementalcost-effectivenessratioforliraglutide1.2 mg,
as, in thissimulation,liraglutide pharmacy costs wereaccounted
Table 2 Treatment effects in the liraglutide vs. glimepiride (previous metformin monotherapy subgroup only) and liraglutide vs. sitagliptin studies
Risk factor
Liraglutide vs. glimepiride Liraglutide vs. sitagliptin
Liraglutide
1.2 mg +
metformin
n =9 1
Liraglutide
1.8 mg +
metformin
n =8 3
Sulphonylurea
+ metformin
n =8 9
Liraglutide
1.2 mg
+ metformin
n = 214
Liraglutide
1.8 mg
+ metformin
n = 211
Sitagliptin
100 mg
+ metformin
n = 210
Change in HbA1c
(mmol⁄mol) (%)
)13.7 (11.2) )14.2 (10.8) )12.7 (10.6) )13.1 (11.0) )16.4 (9.7) )10.0 (11.6)
)1.25 (1.02) )1.30 (0.99) )1.16 (0.97) )1.24 (1.04) )1.50 (0.89) )0.90 (1.04)
Change in systolic
blood pressure
(mmHg)
)3.33 (12.90) )1.18 (12.70) 2.26 (12.65) )0.55 (13.23) )0.72 (13.14) )0.94 (13.17)
Change in total
cholesterol
(mmol⁄l)*
)0.02 (0.82) )0.30 (0.80) 0.09 (0.08) )0.03 (0.82) )0.17 (0.80) )0.02 (0.80)
Change in LDL-C (mmol⁄l)* 0.15 (0.68) 0.13 (0.67) 0.22 (0.67) 0.08 (0.69) 0.05 (0.67) 0.13 (0.68)
Change in HDL-C (mmol⁄l)* 0.02 (0.21) )0.03 (0.20) )0.02 (0.20) 0.00 (0.17) 0.00 (0.17) 0.00 (0.17)
Change in triglycerides
(mmol⁄l)*
)0.44 (1.29) )0.26 (1.26) )0.25 (1.26) )0.19 (1.42) )0.43 (1.37) )0.40 (1.38)
Change in BMI (kg⁄m
2) )0.64 (0.95) )0.75 (1.11) 0.48 (3.69) )1.00 (0.08) )1.18 (0.08) )0.34 (0.08)
Major hypo event rate
(per 100 patient years)
000 100
Minor hypo event rate
(per 100 patient years)
4.9 17.1 217.2 17.8 16.1 10.6
Data are mean (sd).
*The model accepts values in mg⁄dl. The following factors have been used to convert to mmol⁄l: 0.0259 for total cholesterol, LDL-C and
HDL-C, and 0.0113 for triglycerides.
ª 2011 The Authors.
316 Diabetic Medicine ª 2011 Diabetes UK
DIABETICMedicine Cost–utility analysis of liraglutide and metformin combination • M. J. Davies et al.for 8 years, with the same clinical beneﬁt of 5 years’ treatment.
The length of liraglutide treatment for individual patients in a
real-life setting will vary, but it is reassuring to note that
treatment durations of 3, 5 and 8 years are all cost-effective at a
willingness to pay of £20 000 per QALY gained (Table 4).
Similar trends were observed for liraglutide 1.8 mg (data not
shown).
Contribution of clinical effects to QALYs gained
The results of the additional analyses carried out to investigate
the contributionofindividualclinicaleffects(weight,cholesterol
and triglycerides, systolic blood pressure and HbA1c)t oQ A L Y s
showed that the gain in QALYs with liraglutide 1.2 mg over
glimepirideisequallydistributedbetweensystolicbloodpressure
(32%), weight (30%) and cholesterol and triglycerides (27%),
withonlyasmallercontributionfromHbA1c(11%).Conversely,
the gain in QALYs with liraglutide 1.2 mg over sitagliptin arises
mainly from improvements in HbA1c (54%) and weight (44%).
Cholesterolandtriglyceridesandsystolicbloodpressurechanges
had a negligible effect on QALYs gained ()3 and )1%,
respectively). Additional Supporting Information may be found
in the online version of this article.
Discussion
The cost per QALY vs. glimepiride and vs. sitagliptin, for both
doses of liraglutide investigated in this cost–utility modelling
study (1.2 and 1.8 mg), ranged between £9000 and £16 000.
Treatment with liraglutide costs more than with the
comparators, but these increased costs were partially offset by
reductions in the costs associated with complications, because
the risk of developing complications decreases with liraglutide
Table 3 Results of the base-case analysis: quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratios (ICERs)
Liraglutide vs. glimepiride
Liraglutide
1.2 mg
+ metformin
Liraglutide
1.8 mg
+ metformin
Sulphonylurea 4 mg+
metformin
Difference
liraglutide
1.2 mg)
sulphonylurea
Difference
liraglutide
1.8 mg)
sulphonylurea
QALYs 7.76 (0.11) 7.73 (0.10) 7.44 (0.11) 0.32 (0.15) 0.28 (0.14)
Costs (£) 22 122 (502) 23 807 (473) 19 119 (475) 3003 (678) 4688 (639)
ICER
(£ per QALY)
— — — 9449 16 501
Liraglutide vs. sitagliptin
Liraglutide
1.2 mg
+ metformin
Liraglutide
1.8 mg
+ metformin
Sitagliptin
100 mg
+ metformin
Difference
liraglutide
1.2 mg)
sitagliptin
Difference
liraglutide
1.8 mg)
sitagliptin
QALYs 7.52 (0.11) 7.64 (0.11) 7.34 (0.11) 0.19 (0.15) 0.31 (0.15)
Costs (£) 21 793 (544) 23 175 (510) 19 951 (521) 1842 (751) 3224 (683)
ICER (£ per QALY) — — — 9851 10 465
Data are mean (sd).
Liraglutide 1.8 mg
100
90
80
70
60
50
40
30
20
10
0
0 10 000 20 000 30 000 40 000 50 000 60 000
Willingness to pay (£ per QALY gained)
P
r
o
b
a
b
i
l
i
t
y
 
(
%
)
 
t
h
a
t
 
l
i
r
a
g
l
u
t
i
d
e
t
h
e
r
a
p
y
 
w
i
l
l
 
b
e
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
Liraglutide 1.2 mg
FIGURE 1 Cost-effectiveness acceptability curve of liraglutide vs.
glimepiride, base case. QALY, quality-adjusted life year.
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FIGURE 2 Cost-effectiveness acceptability curve of liraglutide vs.
sitagliptin, base case. QALY, quality-adjusted life year.
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DIABETICMedicine Original articletreatment as a result of its combined beneﬁcial effects on body
weight, blood glucose, systolic blood pressure and other
cardiovascular risk factors. The values obtained lie below the
threshold of £20 000–30 000 per QALY, indicating that
liraglutide in combination with metformin monotherapy is a
cost-effective option for the treatment of Type 2 diabetes
compared with glimepiride or sitagliptin. The sensitivity
analyses performed indicated that, in the liraglutide vs.
glimepiride comparison, systolic blood pressure, weight and
cholesterol were the key drivers of cost-effectiveness, with a
relatively small contribution from HbA1c. This was to be
expected, as both liraglutide and glimepiride treatment
achieved similar HbA1c reductions in the clinical trial on which
this health economic evaluation is based, while liraglutide had a
greater impact on reducing systolic blood pressure, weight and
cholesterol compared with glimepiride [10]. In contrast, HbA1c
and weight were the key drivers of cost-effectiveness in the
liraglutide vs. sitagliptin comparison, with only small effects
from systolic blood pressure and cholesterol, reﬂecting the
greater effect of liraglutide vs. sitagliptin on reducing HbA1c and
weight, and the comparable effects of both of these therapies on
systolic blood pressure and cholesterol [11]. In the liraglutide vs.
sitagliptincomparison,apreliminarysubgroupanalysisinwhich
patientswerestratiﬁedbybaselineBMI(all> 30or> 35 kg⁄m
2)
showed that the cost-effectiveness of liraglutide 1.2 mg vs.
sitagliptinimprovedwithincreasingBMI,withincrementalcost-
effectivenessratiosof£9851,£7593and£6125,respectively(see
also Supporting Information, Table S3), probably because
weight loss with liraglutide increases with increasing BMI [19].
This initial ﬁnding is interesting and may warrant further
investigation at a later date. Treatment satisfaction was also
assessed in the liraglutide vs. sitagliptin clinical trial using the
Table 4 Results of the sensitivity analyses: quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratios (ICERs)
Liraglutide vs. glimepiride
Sensitivity analyses
QALYs (years) Costs (£)
ICER
(£ per
QALY
gained)
Liraglutide
1.2 mg
Glimepiride
4 mg Difference
Liraglutide
1.2 mg
Glimepiride
4 mg Difference
Base case 7.76 (0.11) 7.44 (0.11) 0.32 (0.15) 22 122 (502) 19 119 (475) 3003 (678) 9449
3 years’ treatment 7.74 (0.11) 7.44 (0.11) 0.31 (0.15) 21 463 (501) 19 975 (477) 1488 (678) 4859
8 years’ treatment 7.78 (0.11) 7.45 (0.11) 0.33 (0.15) 22 983 (506) 18 005 (472) 4978 (679) 14 950
0% discount rate 10 924 (0.19) 10 418 (0.19) 0.51 (0.26) 34 374 (936) 30 985 (90.3) 3389 (1300) 6696
6% discount rate 6333 (0.10) 6090 (0.10) 0.243 (0.11) 17 108 (358) 14 289 (336) 2818 (476) 11 589
Alternative weight
progression
7.71 (0.11) 7.48 (0.11) 0.23 (0.15) 22 122 (502) 19 119 (475) 3003 (678) 13 175
BMI disutility = )0.0061 8.04 (0.11) 7.77 (0.11) 0.27 (0.16) 22 122 (502) 19 119 (475) 3003 (678) 11 219
Hypoglycaemia
disutility = )0.0052
7.74 (0.11) 7.41 (0.11) 0.33 (0.15) 22 122 (502) 19 119 (475) 3003 (678) 9010
Hypoglycaemia
disutility = 0
7.80 (0.11) 7.51 (0.11) 0.29 (0.15) 22 122 (502) 19 119 (475) 3003 (678) 10 472
Liraglutide vs. sitagliptin
Sensitivity analyses
QALYs (years) Costs (£)
ICER
(£ per
QALY
gained
Liraglutide
1.2 mg
Sitagliptin
100 mg Difference
Liraglutide
1.2 mg
Sitagliptin
100 mg Difference
Base case 7.52 (0.11) 7.34 (0.11) 0.19 (0.15) 21 793 (544) 19 951 (521) 1842 (751) 9851
3 years’ treatment 7.50 (0.10) 7.32 (0.11) 0.18 (0.14) 21 064 (532) 20 270 (521) 793 (737) 4321
8 years’ treatment 7.54 (0.11) 7.35 (0.11) 0.18 (0.15) 22 674 (534) 19 536 (520) 3138 (715) 16 497
0% discount rate 10.49 (0.18) 10.19 (0.19) 0.30 (0.25) 33 565 (971) 31 562 (938) 2003 (1,274) 6720
6% discount rate 6.16 (0.08) 6.02 (0.08) 0.14 (0.11) 16 922 (401) 15 170 (383) 1750 (528) 12 452
Alternative weight
progression
7.44 (0.10) 7.30 (0.11) 0.13 (0.14) 21 793 (544) 19 951 (521) 1842 (715) 13 752
BMI disutility = )0.0061 7.86 (0.11) 7.70 (0.12) 0.16 (0.15) 21 793 (544) 19 951 (521) 1842 (715) 11 637
Hypoglycaemia
disutility = )0.0052
7.50 (0.10) 7.31 (0.11) 0.19 (0.15) 21 793 (544) 19 951 (521) 1842 (715) 9852
Hypoglycaemia
disutility = 0
7.55 (0.11) 7.36 (0.11) 0.19 (0.15) 21 793 (544) 19 951 (521) 1842 (715) 9686
Data are mean (sd).
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patients reported greater treatment satisfaction with liraglutide
[11]. This result was not taken into consideration in the cost–
utility analysis presented here. However, had it been, the cost-
effectiveness of liraglutide vs. sitagliptin may have been even
further enhanced, as treatment satisfaction could translate into
greater adherence and improved clinical outcomes [20].
Furthermore, contrary to the perception that oral treatments
areusuallypreferredtoinjections,therewerenodifferencesinthe
perceived convenience of treatment between sitagliptin and
liraglutide [11].
Toputtheresultsofthiseconomicevaluationintocontext,the
cost per QALY of implementing liraglutide in combination with
metformin therapy estimated in this study is in the same range as
thatestimatedforimplementingeducationprogrammesaimedat
maximizing the beneﬁts of diet and lifestyle interventions as
reported in a recent study, which estimated a cost per QALY
ranging from €10 000 to €39 000 [21]. However, a study that
investigated the cost-effectiveness of the Diabetes Education
and Self management for Ongoing and Newly Diagnosed
(DESMOND) programme in UK patients newly diagnosed
with Type 2 diabetes reported a lower cost per QALY of £2092
[22]. The estimated cost per QALY of adding pioglitazone to
ongoing therapy in patients with Type 2 patients with a history
of macrovascular disease and at high risk for further
cardiovascular events was reported as £5396 vs. placebo after a
mean treatment period of 3 years [23].The cost of adding
sitagliptin to metformin monotherapy vs. the cost of adding a
sulphonylurea appears to also be in the same range as the cost of
adding liraglutide to metformin monotherapy reported here.
An analysis to evaluate the cost of adding sitagliptin vs.
sulphonylurea to metformin monotherapy in patients with
Type 2 diabetes from six European countries (Austria, Finland,
Portugal, Scotland, Spain and Sweden) and not reaching
the International Diabetes Federation’s HbA1c target of
<4 8m m o l⁄mol (< 6.5%) estimated costs per QALY ranging
from €5949 to €20 350 across countries [24]. Similarly, the cost
perlife-yearwithstatins,acommontherapyusedinpatientswith
Type 2 diabetes concomitantly with anti-hyperglycaemic agents
to treat dyslipidaemia and reduce cardiovascular risk, has
been estimated to range from £5400 to £13 300 for primary
prevention and from £3800 to £9300 for secondary prevention.
[25]
Alimitationofthisstudyisthatthemodelused,likeallmodels
used to assess the long-term outcomes of patients with Type 2
diabetes, predicts long-term outcomes based on the results of
short-term studies. However, the CORE Diabetes Model used
here has been validated against published studies that had not
beenusedtoprovideinputdataforsettingupthemodel[13].For
each validation analysis, the progress of a patient cohort from a
published epidemiological, clinical or modelling study was
simulated, and the outcomes of the simulation were compared
with those of the published study. The results indicated that the
CORE Diabetes Model is capable of reliably predicting long-
term patient outcomes.
In conclusion, this study investigated the cost–utility, in a UK
setting, of liraglutide vs. glimepiride or sitagliptin (all added to
metformin monotherapy), scenarios intended to simulate likely
clinical practice in real life. The results suggest that liraglutide
added to metformin monotherapy leads to improvements in
quality adjusted-life expectancy and is a cost-effective option for
the treatment of Type 2 diabetes in this setting.
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